抗ige (Omalizumab)治疗慢性(感冒)接触性荨麻疹成功

IF 0.3 Q4 ALLERGY Astim Allerji Immunoloji Pub Date : 2020-04-17 DOI:10.21911/AAI.455
Ö. Özdemir
{"title":"抗ige (Omalizumab)治疗慢性(感冒)接触性荨麻疹成功","authors":"Ö. Özdemir","doi":"10.21911/AAI.455","DOIUrl":null,"url":null,"abstract":"A 15-year-old male patient presented with complaints of erythema, urticaria and burning on the hands, feet and trunk after contact with cold objects, liquids and/or air for the last two-years. There was no mucosal site involvement and no associated symptoms. The physical examination was normal. The cold provocation test was positive. Biochemistry, hemogram, ESR, CRP, urine analysis, stool examination, latex specific IgE, RF, ANA, skin prick test with common aeroallergens including dust mites, yeasts, animal allergens, various tree and grass pollens, and the serum specific IgE, C3, C4, thyroid function tests, cryoglobulins, cold agglutinins, HIV and HBsAg testing demonstrated normal/negative results. The total IgE level was 5.520 IU/ml in the beginning but decreased to 2.150 IU/ml after 15 months. Due to chronicity of his symptoms and the lack of a triggering factor other than cold, he was diagnosed with type I cold contact urticaria (CCU). Despite using different antihistamines for 10 months, his have persisted. With the use of subcutaneous omalizumab at the dose of 300 mg/month, the symptoms were under control after 3 months (urticaria activity score and Omalizumab was well tolerated. and particularly the severe form (type III) has a considerable effect on the quality of no to been there is no biomarker to predict the response to omalizumab. This case report shows that omalizumab could be useful for the CCU patients.","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2020-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Chronic (Cold) Contact Urticaria Treated Successfully with Anti-IgE (Omalizumab)\",\"authors\":\"Ö. Özdemir\",\"doi\":\"10.21911/AAI.455\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A 15-year-old male patient presented with complaints of erythema, urticaria and burning on the hands, feet and trunk after contact with cold objects, liquids and/or air for the last two-years. There was no mucosal site involvement and no associated symptoms. The physical examination was normal. The cold provocation test was positive. Biochemistry, hemogram, ESR, CRP, urine analysis, stool examination, latex specific IgE, RF, ANA, skin prick test with common aeroallergens including dust mites, yeasts, animal allergens, various tree and grass pollens, and the serum specific IgE, C3, C4, thyroid function tests, cryoglobulins, cold agglutinins, HIV and HBsAg testing demonstrated normal/negative results. The total IgE level was 5.520 IU/ml in the beginning but decreased to 2.150 IU/ml after 15 months. Due to chronicity of his symptoms and the lack of a triggering factor other than cold, he was diagnosed with type I cold contact urticaria (CCU). Despite using different antihistamines for 10 months, his have persisted. With the use of subcutaneous omalizumab at the dose of 300 mg/month, the symptoms were under control after 3 months (urticaria activity score and Omalizumab was well tolerated. and particularly the severe form (type III) has a considerable effect on the quality of no to been there is no biomarker to predict the response to omalizumab. This case report shows that omalizumab could be useful for the CCU patients.\",\"PeriodicalId\":42004,\"journal\":{\"name\":\"Astim Allerji Immunoloji\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2020-04-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Astim Allerji Immunoloji\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21911/AAI.455\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Astim Allerji Immunoloji","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21911/AAI.455","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

摘要

一名15岁男性患者在过去两年中接触冷物体、液体和/或空气后,出现红斑、荨麻疹和手、脚和躯干烧伤。没有粘膜部位受累,也没有相关症状。身体检查正常。冷激试验呈阳性。生物化学、血象、ESR、CRP、尿液分析、粪便检查、乳胶特异性IgE、RF、ANA、常见空气过敏原(包括尘螨、酵母、动物过敏原、各种树木和草花粉)的皮肤点刺试验,以及血清特异性IgE、C3、C4、甲状腺功能试验、冷球蛋白、冷凝集素、HIV和HBsAg试验均显示正常/阴性结果。总IgE水平在开始时为5.520 IU/ml,但在15个月后降至2.150 IU/ml。由于他的症状是慢性的,并且除了感冒之外没有其他触发因素,他被诊断为I型感冒接触性荨麻疹(CCU)。尽管使用了不同的抗组胺药达10个月之久,但他的坚持了下来。皮下使用300mg/月剂量的奥马珠单抗,3个月后症状得到控制(荨麻疹活动评分和奥马珠珠单抗耐受性良好。尤其是严重型(III型)对no的质量有相当大的影响。目前还没有生物标志物来预测对奥马珠mab的反应。该病例报告显示奥马珠单抗可能对CCU患者有用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Chronic (Cold) Contact Urticaria Treated Successfully with Anti-IgE (Omalizumab)
A 15-year-old male patient presented with complaints of erythema, urticaria and burning on the hands, feet and trunk after contact with cold objects, liquids and/or air for the last two-years. There was no mucosal site involvement and no associated symptoms. The physical examination was normal. The cold provocation test was positive. Biochemistry, hemogram, ESR, CRP, urine analysis, stool examination, latex specific IgE, RF, ANA, skin prick test with common aeroallergens including dust mites, yeasts, animal allergens, various tree and grass pollens, and the serum specific IgE, C3, C4, thyroid function tests, cryoglobulins, cold agglutinins, HIV and HBsAg testing demonstrated normal/negative results. The total IgE level was 5.520 IU/ml in the beginning but decreased to 2.150 IU/ml after 15 months. Due to chronicity of his symptoms and the lack of a triggering factor other than cold, he was diagnosed with type I cold contact urticaria (CCU). Despite using different antihistamines for 10 months, his have persisted. With the use of subcutaneous omalizumab at the dose of 300 mg/month, the symptoms were under control after 3 months (urticaria activity score and Omalizumab was well tolerated. and particularly the severe form (type III) has a considerable effect on the quality of no to been there is no biomarker to predict the response to omalizumab. This case report shows that omalizumab could be useful for the CCU patients.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.80
自引率
0.00%
发文量
10
期刊介绍: Asthma Allergy Immunology has been published three times a year in April, August and December as the official and periodical journal of the Turkish National Society of Allergy and Clinical Immunology since 2003. All articles published in the journal have been available online since 2003. A peer reviewed system is used in evaluation of the manuscripts submitted to Asthma Allergy Immunology. The official language of the journal is English. The aim of the journal is to present advances in the field of allergic diseases and clinical immunology to the readers. In accordance with this goal, manuscripts in the format of original research, review, case report, articles about clinical and practical applications and editorials, short report and letters to the editor about allergic diseases and clinical immunology are published in the journal. The target reader population of the Asthma Allergy Immunology includes specialists and residents of allergy and clinical immunology, pulmonology, internal medicine, pediatrics, dermatology and otolaryngology as well as physicians working in other fields of medicine interested in allergy and immunological diseases.
期刊最新文献
Delayed Urticaria- Angioedema After mRNA Vaccine in an Adolescent Patient: Case Report A Father and Son Diagnosed with DiGeorge Syndrome DRESS Syndrome due to Carbamazepine Use in A Drug-Addicted Adolescent FROM THE EDITOR Identification of Novel Endochitinase Class I Based Allergens
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1